Thus, future studies should integrate genomic profiling and ABL1 kinase mutation analysis to elucidate the mechanisms mediated by an NK that lead to inferior outcomes in patients with BCR-ABL1+ ALL. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.